USA – Panome Bio, a St Louis-based metabolomics and proteomics services company that provides biopharma innovators access into the biomolecules closest to phenotype and function, closed a growth financing round of undisclosed amount.
The round was led by Telegraph Hill Partners, with participation from BioGenerator Ventures. Deval Lashkari, Rob Capone, and Alex Herzick from Telegraph Hill Partners will join Panome Bio’s board of directors. Edward Weinstein, Chief Executive Officer and Co-founder, and David Smoller, Co-founder, will also hold seats on the Panome Bio Board.The financing will be used to develop new technologies and capabilities, expand laboratory facilities, and grow the Panome Bio team to service the increasing interest in metabolomics and proteomics data.Launched around the Next-Generation Metabolomics™ technology developed by Chief Scientific Officer, Dr. Gary Patti, and led by CEO Edward Weinstein, Panome has developed a platform that uses advanced liquid chromatography – mass spectrometry assays and proprietary bioinformatic tools to gain actionable insights to metabolic pathways involved in cancer, aging, drug metabolism, and other areas. The company works with pharmaceutical and biotech companies and pairs Next-Generation Metabolomics with high-throughput proteomics to further advance research in biomarker discovery and drug development.Dr. Patti is also the Michael and Tana Powell Professor at Washington University in Saint Louiswhere his lab is a leader in the field of metabolomics. He is known for many key advancements including developing gold-standard metabolomics analysis software and workflow optimization that allow for global metabolomics screens.
